Find the Right Companion Diagnostic

VENTANA HER2 Dual ISH DNA Probe Cocktail is an FDA-approved, dual-color chromogenic in situ hybridization assay that uses HER2 and chromosome 17 DNA probes to assess HER2 gene amplification in FFPE breast and gastric or gastroesophageal junction cancer tissue. Performed on VENTANA BenchMark instruments, it reports HER2/Chr17 ratios to classify tumors as HER2-negative or HER2-amplified for treatment planning.

PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody is an FDA-approved, semi-quantitative immunohistochemistry reagent for detecting HER2 antigen in formalin-fixed, paraffin-embedded breast and gastric tissue on VENTANA BenchMark IHC/ISH instruments. Using standardized 0–3+ membrane staining criteria, it classifies tumors by HER2 protein expression to support HER2-directed treatment decisions.

Oncomine Dx Target Test is an FDA-approved, qualitative targeted NGS assay performed on the Ion PGM Dx System. Using DNA and RNA from FFPE tumor tissue, it detects single-nucleotide variants, insertions, deletions, and fusions in a defined panel of cancer driver genes. It is approved for use in NSCLC and several other solid tumors to characterize oncogenic alterations and support selection of targeted treatment strategies.